

iQnovate Ltd announces Private Placement

Dear iQnovate shareholders and friends,

iQnovate Ltd (NSX: IQN, GXG: IQN, OTCQB: IQNDY) today announced a private placement of \$5million in the company's shares with professional and sophisticated investors.

Funds raised from the placement will be applied towards acquiring the intellectual property rights pertaining to the development of a biopharmaceutical compound portfolio.

The placement is anticipated to be completed during the 3rd quarter of 2015.

This is the third announcement of iQnovate in the past two weeks. This follows the announcement of commencing the process for iQnovate to be cross-listed on NASDAQ and the announcement regarding the listing of its wholly owned subsidiary "FarmaForce Pty Ltd".

The CEO of iQnovate Ltd, Dr George Syrmalis, said: "This Placement puts iQnovate in a strong financial position to progress its current activities and negotiations throughout 2015 and will tactically position the company to advance its ongoing business plan."

Click [here](#) view the market announcement.

If you have any queries about the announcement, please contact our Investor Relations team investor.relations@iqnovate.com on +61 2 8239 5400.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE

iQnovate Limited

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry. Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity. iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400 • Fax: +61 2 8362 9325

New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •

London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK •